369 related articles for article (PubMed ID: 20041839)
1. Cardiovascular disease: what's all the AGE/RAGE about?
Barlovic DP; Thomas MC; Jandeleit-Dahm K
Cardiovasc Hematol Disord Drug Targets; 2010 Mar; 10(1):7-15. PubMed ID: 20041839
[TBL] [Abstract][Full Text] [Related]
2. The role of AGEs in cardiovascular disease.
Jandeleit-Dahm K; Cooper ME
Curr Pharm Des; 2008; 14(10):979-86. PubMed ID: 18473849
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
4. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
5. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
Schmidt AM; Yan SD; Wautier JL; Stern D
Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
[TBL] [Abstract][Full Text] [Related]
6. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
[TBL] [Abstract][Full Text] [Related]
7. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose.
Yan SD; Stern D; Schmidt AM
Eur J Clin Invest; 1997 Mar; 27(3):179-81. PubMed ID: 9088851
[No Abstract] [Full Text] [Related]
8. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
[TBL] [Abstract][Full Text] [Related]
9. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
Pertynska-Marczewska M; Merhi Z
Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634
[TBL] [Abstract][Full Text] [Related]
10. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention.
Yamagishi SI
Circ J; 2019 Aug; 83(9):1822-1828. PubMed ID: 31366777
[TBL] [Abstract][Full Text] [Related]
11. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.
Stern DM; Yan SD; Yan SF; Schmidt AM
Ageing Res Rev; 2002 Feb; 1(1):1-15. PubMed ID: 12039445
[TBL] [Abstract][Full Text] [Related]
12. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Jandeleit-Dahm K; Watson A; Soro-Paavonen A
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
[TBL] [Abstract][Full Text] [Related]
13. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs).
Yamagishi S; Matsui T
Curr Drug Targets; 2010 Jul; 11(7):875-81. PubMed ID: 20412043
[TBL] [Abstract][Full Text] [Related]
14. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation.
Lanati N; Emanuele E; Brondino N; Geroldi D
Curr Vasc Pharmacol; 2010 Jan; 8(1):86-92. PubMed ID: 19485931
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.
Yap FY; Kantharidis P; Coughlan MT; Slattery R; Forbes JM
Curr Drug Targets; 2012 Apr; 13(4):526-40. PubMed ID: 22250649
[TBL] [Abstract][Full Text] [Related]
16. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
[TBL] [Abstract][Full Text] [Related]
17. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker.
Yamagishi S; Matsui T
Front Biosci (Elite Ed); 2010 Jun; 2(4):1184-95. PubMed ID: 20515790
[TBL] [Abstract][Full Text] [Related]
18. RAGE: a multi-ligand receptor unveiling novel insights in health and disease.
Alexiou P; Chatzopoulou M; Pegklidou K; Demopoulos VJ
Curr Med Chem; 2010; 17(21):2232-52. PubMed ID: 20459381
[TBL] [Abstract][Full Text] [Related]
19. Role of advanced glycation end products in diabetic neuropathy.
Sugimoto K; Yasujima M; Yagihashi S
Curr Pharm Des; 2008; 14(10):953-61. PubMed ID: 18473845
[TBL] [Abstract][Full Text] [Related]
20. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
Yan SF; Ramasamy R; Schmidt AM
J Mol Med (Berl); 2009 Mar; 87(3):235-47. PubMed ID: 19189073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
